🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT03520101
Active, not recruiting Not applicable

Comparison of the Balloon-Expandable Edwards Valve and Self-Expandable CoreValve Evolut R or Evolut PRO System for the Treatment of Small, Severely Dysfunctional Surgical Aortic Bioprotheses. The 'LYTEN' Trial

NCT03520101 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2017-05-10
Last updated
2026-03-27

Condition(s) studied

Aortic Valve StenosisRegurgitation, AorticProsthesis Failure

Investigational drug(s) / intervention(s)

TAVI_ViV procedure with Edwards valveTAVI_ViV procedure with CoreValve system

TAVI_ViV procedure with Edwards valve: The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local anesthesia, imaging guidance during the TAVI procedure, and post-procedural TAVI management. The decision for selecting either a 20 or 23mm Edwards valve will be based on 3D CT measurements of the mean inner diameter of the surgical aortic bioprosthesis. A 23mm Sapien 3 valve will be recommended if the inner diameter is \>18 mm, and a 20mm valve will be selected if the mean inner diameter is ≤18 mm.

TAVI_ViV procedure with CoreValve system: The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local anesthesia, imaging guidance during the TAVI procedure, and post-procedural TAVI management. A 23mm valve will be recommended in all patients randomized to the self-expanding CoreValve Evolut R system.

Study summary

The treatment with transcatheter aortic valve implantation (TAVI) of patients with small (≤23mm) surgical bioprostheses remains a challenge due to the increased transvalvular residual gradients and high rates of severe prosthesis-patient mismatch (PPM) following the procedure.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with surgical aortic bioprosthetic dysfunction defined as severe aortic stenosis and/or regurgitation approved for a ViV procedure by the Heart Team * Stented surgical valves. * Small (≤23mm) surgical valve Exclusion Criteria: \- Stentless or sutureless surgical valves

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
IUCPQ Québec Quebec

More Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03520101 on ClinicalTrials.gov ↗ ← All trials in Canada